Focus Partners Wealth Acquires 22,132 Shares of Merck & Co., Inc. $MRK

Focus Partners Wealth boosted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 1.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,235,786 shares of the company’s stock after acquiring an additional 22,132 shares during the period. Focus Partners Wealth’s holdings in Merck & Co., Inc. were worth $103,753,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. Brighton Jones LLC boosted its position in shares of Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after purchasing an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC increased its position in Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after buying an additional 3,941 shares in the last quarter. Foundations Investment Advisors LLC increased its position in Merck & Co., Inc. by 10.6% during the 2nd quarter. Foundations Investment Advisors LLC now owns 26,831 shares of the company’s stock valued at $2,124,000 after buying an additional 2,565 shares in the last quarter. Security Financial Services INC. raised its stake in Merck & Co., Inc. by 12.2% during the second quarter. Security Financial Services INC. now owns 2,823 shares of the company’s stock valued at $223,000 after buying an additional 308 shares during the last quarter. Finally, Empower Advisory Group LLC raised its stake in Merck & Co., Inc. by 7.1% during the second quarter. Empower Advisory Group LLC now owns 166,897 shares of the company’s stock valued at $13,212,000 after buying an additional 11,043 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 121,573 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $119.15, for a total value of $14,485,422.95. Following the completion of the transaction, the executive vice president owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Richard R. Deluca sold 37,685 shares of the company’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the transaction, the executive vice president owned 160,174 shares in the company, valued at $19,368,240.08. This represents a 19.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 320,176 shares of company stock worth $38,281,735 in the last three months. 0.09% of the stock is currently owned by company insiders.

Merck & Co., Inc. Stock Performance

MRK stock opened at $115.61 on Monday. The stock’s 50 day simple moving average is $115.26 and its 200 day simple moving average is $99.79. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The stock has a market capitalization of $285.84 billion, a PE ratio of 15.88, a price-to-earnings-growth ratio of 2.24 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business had revenue of $16.40 billion during the quarter, compared to analyst estimates of $16.19 billion. During the same quarter last year, the company earned $1.72 EPS. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 46.70%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Wall Street Analysts Forecast Growth

MRK has been the topic of several analyst reports. The Goldman Sachs Group boosted their target price on Merck & Co., Inc. from $92.00 to $120.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. Wolfe Research upgraded shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price target on the stock in a research note on Thursday, January 8th. Citigroup increased their price objective on shares of Merck & Co., Inc. from $115.00 to $120.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Finally, Guggenheim raised their price objective on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research note on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $126.81.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.